{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:31:07Z","timestamp":1790087467018,"version":"4.0.1"},"reference-count":32,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Plasmacytoid urothelial carcinoma (PC-UC) is an aggressive variant of urothelial carcinoma (UC), characterized by loss of E-cadherin (E-Cad)\u2013mediated intercellular adhesion. Loss of E-Cad by immunohistochemistry can help diagnose PC-UC; however, sensitivity is limited. Expression of other cadherin-catenin adhesion complex members, that is, p-120 catenin (p-120) and \u03b2-catenin (B-Cat), which are diagnostically useful for lobular breast carcinoma, remains unknown in UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To determine the utility of p-120 and B-Cat in conventional and variant UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>E-cadherin, B-Cat, and p-120 immunohistochemistry was performed in 25 conventional UCs and 33 variant UCs, including 22 PC-UCs, 6 sarcomatoid UCs (SUCs), and 5 micropapillary UCs. Membranous staining for all biomarkers was considered normal; however, any cytoplasmic staining or an absence of staining was considered diagnostically abnormal. Next-generation sequencing was performed on 8 PC-UC cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>E-cadherin, B-Cat, and p-120 showed membranous staining in all conventional and micropapillary UCs. In contrast, most PC-UCs were negative for E-Cad (17 of 22; 77%) with an additional 2 of 22 cases (9%) showing cytoplasmic with partial membranous staining. p-120 catenin demonstrated cytoplasmic or negative staining in 21 of 22 cases (95%). Most SUCs showed an absence of E-Cad (5 of 6; 83%) and cytoplasmic or negative p-120 in 5 of 6 cases (83%). Staining for B-Cat was also abnormal in a subset of PC-UCs and SUCs. Five PC-UC cases that harbored CDH1 gene variants were p-120 cytoplasmic positive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>p-120 catenin is a useful adjunct biomarker to E-Cad in the clinically important distinction of PC-UC and SUC from conventional UC. In particular, the combination of cytoplasmic p-120 and loss of E-Cad is strongly supportive of PC-UC and SUC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0262-oa","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:50:22Z","timestamp":1606308622000},"page":"1000-1008","source":"Crossref","is-referenced-by-count":8,"title":["p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma"],"prefix":"10.5858","volume":"145","author":[{"given":"Andres M.","family":"Acosta","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Acosta, Barletta, Schnitt, Hirsch)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Barletta","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Acosta, Barletta, Schnitt, Hirsch)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"The Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts (Sonpavde)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Schnitt","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Acosta, Barletta, Schnitt, Hirsch)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Hirsch","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Acosta, Barletta, Schnitt, Hirsch)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"2021080319422329200_i1543-2165-145-8-1000-b01","doi-asserted-by":"crossref","unstructured":"Zukerberg\n              LR,\n            \n            \n              Harris\n              NL,\n            \n            \n              Young\n              RH.\n            \n          \n          Carcinomas of the urinary bladder simulating malignant lymphoma: a report of five cases.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t1991;\n\t\t\t\t\t15(6):\n\t\t\t\t\t569\u2013\n\t\t\t\t\t576.","DOI":"10.1097\/00000478-199106000-00005"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b02","unstructured":"Grignon\n              DJ,\n            \n            \n              Al-Ahmadie\n              H,\n            \n            \n              Algaba\n              F,\n            \n            et al.\n          \n          Infiltrating urothelial carcinoma.\n\t\t\t\t\tIn:MochH,PAHumphrey,UlbrightTM,ReuterV,eds.WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed.\n\t\t\t\t\tLyon, France:\n\t\t\t\t\tInternational Agency for Research on Cancer (IARC);2016:\n\t\t\t\t\t81\u2013\n\t\t\t\t\t98."},{"key":"2021080319422329200_i1543-2165-145-8-1000-b03","unstructured":"Bladder cancer: non-urothelial and urothelial with variant histology.\n\t\t\t\t\tIn:NCCN Guidelines Version 4.2019: bladder cancer.\n\t\t\t\t\thttps:\/\/www2.tri-kobe.org\/nccn\/guideline\/urological\/english\/bladder.pdf. Accessed September 17, 2020."},{"key":"2021080319422329200_i1543-2165-145-8-1000-b04","doi-asserted-by":"crossref","unstructured":"Fox\n              MD,\n            \n            \n              Xiao\n              L,\n            \n            \n              Zhang\n              M,\n            \n            et al.\n          \n          Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2017;\n\t\t\t\t\t147(5):\n\t\t\t\t\t500\u2013\n\t\t\t\t\t506.","DOI":"10.1093\/ajcp\/aqx029"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b05","doi-asserted-by":"crossref","unstructured":"Lim\n              MG,\n            \n            \n              Adsay\n              NV,\n            \n            \n              Grignon\n              DJ,\n            \n            et al.\n          \n          E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2011;\n\t\t\t\t\t24(2):\n\t\t\t\t\t241\u2013\n\t\t\t\t\t247.","DOI":"10.1038\/modpathol.2010.187"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b06","doi-asserted-by":"crossref","unstructured":"Al-Ahmadie\n              HA,\n            \n            \n              Iyer\n              G,\n            \n            \n              Lee\n              BH,\n            \n            et al.\n          \n          Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.\n\t\t\t\t\tNat Genet.\n\t\t\t\t\t2016;\n\t\t\t\t\t48(4):\n\t\t\t\t\t356\u2013\n\t\t\t\t\t358.","DOI":"10.1038\/ng.3503"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b07","doi-asserted-by":"crossref","unstructured":"Dent\n              ED.\n            \n          \n          Carcinosarcoma (collision tumor) of the urinary bladder.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t1955;\n\t\t\t\t\t74(1):\n\t\t\t\t\t104\u2013\n\t\t\t\t\t108.","DOI":"10.1016\/S0022-5347(17)67250-1"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b08","doi-asserted-by":"crossref","unstructured":"Sanfrancesco\n              J,\n            \n            \n              McKenney\n              JK,\n            \n            \n              Leivo\n              MZ,\n            \n            et al.\n          \n          Sarcomatoid urothelial carcinoma of the bladder: Analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2016;\n\t\t\t\t\t140(6):\n\t\t\t\t\t543\u2013\n\t\t\t\t\t551.","DOI":"10.5858\/arpa.2015-0085-OA"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b09","doi-asserted-by":"crossref","unstructured":"M\u00e8ge\n              RM,\n            \n            \n              Ishiyama\n              N.\n            \n          \n          Integration of cadherin adhesion and cytoskeleton at adherens junctions.\n\t\t\t\t\tCold Spring Harb Perspect Biol.\n\t\t\t\t\t2017;\n\t\t\t\t\t9(5):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t18.","DOI":"10.1101\/cshperspect.a028738"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b10","doi-asserted-by":"crossref","unstructured":"Peifer\n              M,\n            \n            \n              Yap\n              AS.\n            \n          \n          Traffic control: P-120-catenin acts as a gatekeeper to control the fate of classical cadherins in mammalian cells.\n\t\t\t\t\tJ Cell Biol.\n\t\t\t\t\t2003;\n\t\t\t\t\t163(3):\n\t\t\t\t\t437\u2013\n\t\t\t\t\t440.","DOI":"10.1083\/jcb.200310090"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b11","doi-asserted-by":"crossref","unstructured":"Schackmann\n              RCJ,\n            \n            \n              Tenhagen\n              M,\n            \n            \n              van de Ven\n              RAH,\n            \n            et al.\n          \n          P-120-catenin in cancer\u2014mechanisms, models and opportunities for intervention.\n\t\t\t\t\tJ Cell Sci.\n\t\t\t\t\t2013;\n\t\t\t\t\t126(16):\n\t\t\t\t\t3515\u2013\n\t\t\t\t\t3525.","DOI":"10.1242\/jcs.134411"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b12","doi-asserted-by":"crossref","unstructured":"Da Silva\n              L,\n            \n            \n              Parry\n              S,\n            \n            \n              Reid\n              L,\n            \n            et al.\n          \n          Aberrant expression of e-cadherin in lobular carcinomas of the breast.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2008;\n\t\t\t\t\t32(5):\n\t\t\t\t\t773\u2013\n\t\t\t\t\t783.","DOI":"10.1097\/PAS.0b013e318158d6c5"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b13","doi-asserted-by":"crossref","unstructured":"Rakha\n              EA,\n            \n            \n              Patel\n              A,\n            \n            \n              Powe\n              DG,\n            \n            et al.\n          \n          Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2010;\n\t\t\t\t\t34(10):\n\t\t\t\t\t1472\u2013\n\t\t\t\t\t1479.","DOI":"10.1097\/PAS.0b013e3181f01916"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b14","doi-asserted-by":"crossref","unstructured":"Dabbs\n              DJ,\n            \n            \n              Bhargava\n              R,\n            \n            \n              Chivukula\n              M.\n            \n          \n          Lobular versus ductal breast neoplasms.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2007;\n\t\t\t\t\t31(3):\n\t\t\t\t\t427\u2013\n\t\t\t\t\t437.","DOI":"10.1097\/01.pas.0000213386.63160.3f"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b15","doi-asserted-by":"crossref","unstructured":"Garcia\n              EP,\n            \n            \n              Minkovsky\n              A,\n            \n            \n              Jia\n              Y,\n            \n            et al.\n          \n          Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t141(6):\n\t\t\t\t\t751\u2013\n\t\t\t\t\t758.","DOI":"10.5858\/arpa.2016-0527-OA"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b16","doi-asserted-by":"crossref","unstructured":"Sholl\n              LM,\n            \n            \n              Do\n              K,\n            \n            \n              Shivdasani\n              P,\n            \n            et al.\n          \n          Institutional implementation of clinical tumor profiling on an unselected cancer population.\n\t\t\t\t\tJCI Insight.\n\t\t\t\t\t2016;\n\t\t\t\t\t1(19):\n\t\t\t\t\te87062.","DOI":"10.1172\/jci.insight.87062"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b17","doi-asserted-by":"crossref","unstructured":"Hui\n              Y,\n            \n            \n              Lombardo\n              KA,\n            \n            \n              Quddus\n              MR,\n            \n            \n              Matoso\n              A.\n            \n          \n          Cell polarity reversal distinguishes true micropapillary growth from retraction artifact in invasive urothelial carcinoma.\n\t\t\t\t\tAppl Immunohistochem Mol Morphol.\n\t\t\t\t\t2018;\n\t\t\t\t\t26(1):\n\t\t\t\t\te1\u2013\n\t\t\t\t\te6.","DOI":"10.1097\/PAI.0000000000000566"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b18","doi-asserted-by":"crossref","unstructured":"Robertson\n              AG,\n            \n            \n              Kim\n              J,\n            \n            \n              Al-Ahmadie\n              H,\n            \n            et al.\n          \n          Comprehensive molecular characterization of muscle-invasive bladder cancer.\n\t\t\t\t\tCell.\n\t\t\t\t\t2017;\n\t\t\t\t\t171(3):\n\t\t\t\t\t540\u2013\n\t\t\t\t\t556.","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b19","doi-asserted-by":"crossref","unstructured":"Keck\n              B,\n            \n            \n              Stoehr\n              R,\n            \n            \n              Wach\n              S,\n            \n            et al.\n          \n          The plasmacytoid carcinoma of the bladder\u2014rare variant of aggressive urothelial carcinoma.\n\t\t\t\t\tInt J Cancer2011;\n\t\t\t\t\t129(2):\n\t\t\t\t\t346\u2013\n\t\t\t\t\t354.","DOI":"10.1002\/ijc.25700"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b20","doi-asserted-by":"crossref","unstructured":"Keck\n              B,\n            \n            \n              Wach\n              S,\n            \n            \n              Stoehr\n              R,\n            \n            et al.\n          \n          Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy.\n\t\t\t\t\tBMC Cancer.\n\t\t\t\t\t2013;\n\t\t\t\t\t13:\n\t\t\t\t\t71.","DOI":"10.1186\/1471-2407-13-71"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b21","doi-asserted-by":"crossref","unstructured":"Keck\n              B,\n            \n            \n              Wach\n              S,\n            \n            \n              Kunath\n              F,\n            \n            et al.\n          \n          Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.\n\t\t\t\t\tAnn Surg Oncol.\n\t\t\t\t\t2013;\n\t\t\t\t\t20(7):\n\t\t\t\t\t2440\u2013\n\t\t\t\t\t2445.","DOI":"10.1245\/s10434-012-2709-4"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b22","doi-asserted-by":"crossref","unstructured":"Li\n              Q,\n            \n            \n              Assel\n              M,\n            \n            \n              Benfante\n              NE,\n            \n            et al.\n          \n          The impact of plasmacytoid variant histology on the survival of patients with urothelial carcinoma of bladder after radical cystectomy.\n\t\t\t\t\tEur Urol Focus.\n\t\t\t\t\t2019;\n\t\t\t\t\t5(1):\n\t\t\t\t\t104\u2013\n\t\t\t\t\t108.","DOI":"10.1016\/j.euf.2017.06.013"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b23","doi-asserted-by":"crossref","unstructured":"Wright\n              JL,\n            \n            \n              Black\n              PC,\n            \n            \n              Brown\n              GA,\n            \n            et al.\n          \n          Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2007;\n\t\t\t\t\t178(6):\n\t\t\t\t\t2302\u2013\n\t\t\t\t\t2306.","DOI":"10.1016\/j.juro.2007.08.038"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b24","doi-asserted-by":"crossref","unstructured":"Dayyani\n              F,\n            \n            \n              Czerniak\n              BA,\n            \n            \n              Sircar\n              K,\n            \n            et al.\n          \n          Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2013;\n\t\t\t\t\t189(5):\n\t\t\t\t\t1656\u2013\n\t\t\t\t\t1661.","DOI":"10.1016\/j.juro.2012.11.084"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b25","doi-asserted-by":"crossref","unstructured":"Ricardo-Gonzalez\n              RR,\n            \n            \n              Nguyen\n              M,\n            \n            \n              Gokden\n              N,\n            \n            et al.\n          \n          Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2012;\n\t\t\t\t\t187(3):\n\t\t\t\t\t852\u2013\n\t\t\t\t\t855.","DOI":"10.1016\/j.juro.2011.10.145"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b26","doi-asserted-by":"crossref","unstructured":"Warrick\n              JI.\n            \n          \n          Clinical significance of histologic variants of bladder cancer.\n\t\t\t\t\tJ Natl Compr Canc Netw.\n\t\t\t\t\t2017;\n\t\t\t\t\t15(10):\n\t\t\t\t\t1268\u2013\n\t\t\t\t\t1274.","DOI":"10.6004\/jnccn.2017.7027"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b27","doi-asserted-by":"crossref","unstructured":"Sangoi\n              AR,\n            \n            \n              Beck\n              AH,\n            \n            \n              Amin\n              MB,\n            \n            et al.\n          \n          Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2010;\n\t\t\t\t\t34(9):\n\t\t\t\t\t1367\u2013\n\t\t\t\t\t1376.","DOI":"10.1097\/PAS.0b013e3181ec86b3"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b28","doi-asserted-by":"crossref","unstructured":"Genitsch\n              V,\n            \n            \n              Koll\u00e1r\n              A,\n            \n            \n              Vandekerkhove\n              G,\n            \n            et al.\n          \n          Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.\n\t\t\t\t\tUrol Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t37(11):\n\t\t\t\t\t826\u2013\n\t\t\t\t\t836.","DOI":"10.1016\/j.urolonc.2019.09.025"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b29","doi-asserted-by":"crossref","unstructured":"Soto\n              E,\n            \n            \n              Yanagisawa\n              M,\n            \n            \n              Marlow\n              LA,\n            \n            et al.\n          \n          P-120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression.\n\t\t\t\t\tJ Cell Biol.\n\t\t\t\t\t2008;\n\t\t\t\t\t183(4):\n\t\t\t\t\t737\u2013\n\t\t\t\t\t749.","DOI":"10.1083\/jcb.200805113"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b30","doi-asserted-by":"crossref","unstructured":"Shibata\n              T,\n            \n            \n              Kokubu\n              A,\n            \n            \n              Sekine\n              S,\n            \n            et al.\n          \n          Cytoplasmic P-120ctn regulates the invasive phenotypes of E-cadherin-deficient breast cancer.\n\t\t\t\t\tAm J Pathol.\n\t\t\t\t\t2004;\n\t\t\t\t\t164(6):\n\t\t\t\t\t2269\u2013\n\t\t\t\t\t2278.","DOI":"10.1016\/S0002-9440(10)63783-2"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b31","doi-asserted-by":"crossref","unstructured":"Schackmann\n              RCJ,\n            \n            \n              Klarenbeek\n              S,\n            \n            \n              Vlug\n              EJ,\n            \n            et al.\n          \n          Loss of P-120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2013;\n\t\t\t\t\t73(15):\n\t\t\t\t\t4937\u2013\n\t\t\t\t\t4949.","DOI":"10.1158\/0008-5472.CAN-13-0180"},{"key":"2021080319422329200_i1543-2165-145-8-1000-b32","doi-asserted-by":"crossref","unstructured":"Bellovin\n              DI,\n            \n            \n              Bates\n              RC,\n            \n            \n              Muzikansky\n              A,\n            \n            et al.\n          \n          Altered localization of P-120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease.\n\t\t\t\t\tCancer Res.\n\t\t\t\t\t2005;\n\t\t\t\t\t65(23):\n\t\t\t\t\t10938\u2013\n\t\t\t\t\t10945.","DOI":"10.1158\/0008-5472.CAN-05-1947"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/8\/1000\/2878802\/i1543-2165-145-8-1000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/8\/1000\/2878802\/i1543-2165-145-8-1000.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:39:07Z","timestamp":1764790747000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/8\/article-p1000.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,11,25]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0262-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}